PTC Therapeutics Valuation
| PTCT Stock | USD 69.45 1.25 1.77% |
At this time, the company appears to be undervalued. PTC Therapeutics owns a latest Real Value of $81.07 per share. The recent price of the company is $69.45. Our model determines the value of PTC Therapeutics from examining the company fundamentals such as return on asset of 0.26, and Operating Margin of 0.02 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting PTC Therapeutics' valuation include:
Undervalued
Today
Please note that PTC Therapeutics' price fluctuation is very steady at this time. Calculation of the real value of PTC Therapeutics is based on 3 months time horizon. Increasing PTC Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
PTC Therapeutics' intrinsic value may or may not be the same as its current market price of 69.45, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 69.45 | Real 81.07 | Target 88.5 | Hype 69.43 |
The intrinsic value of PTC Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence PTC Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of PTC Therapeutics helps investors to forecast how PTC stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PTC Therapeutics more accurately as focusing exclusively on PTC Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use PTC Therapeutics' intrinsic value based on its ongoing forecasts of PTC Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against PTC Therapeutics' closest peers.
PTC Therapeutics Cash |
|
PTC Revenue by Product
PTC Therapeutics Total Value Analysis
PTC Therapeutics is at this time forecasted to have valuation of 4.3 B with market capitalization of 5.58 B, debt of 2.47 B, and cash on hands of 288.43 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the PTC Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.3 B | 5.58 B | 2.47 B | 288.43 M |
PTC Therapeutics Investor Information
About 97.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 0.81. PTC Therapeutics recorded earning per share (EPS) of 8.6. The entity had not issued any dividends in recent years. Based on the key indicators related to PTC Therapeutics' liquidity, profitability, solvency, and operating efficiency, PTC Therapeutics may be sliding down financialy. It has an above-average odds of going through some form of financial crisis next quarter.PTC Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PTC Therapeutics has an asset utilization ratio of 47.32 percent. This implies that the Company is making $0.47 for each dollar of assets. An increasing asset utilization means that PTC Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.PTC Therapeutics Profitability Analysis
Based on PTC Therapeutics' profitability indicators, PTC Therapeutics' profitability may be sliding down. It has an above-average odds of reporting lower numbers next quarter. Profitability indicators assess PTC Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2004-12-31 | Previous Quarter -64.8 M | Current Value 15.9 M | Quarterly Volatility 133.7 M |
For PTC Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PTC Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PTC Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PTC Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PTC Therapeutics over time as well as its relative position and ranking within its peers.
PTC Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of PTC Therapeutics is estimated to be -0.2175 with future projections ranging from a low of -0.87 to a high of 0.2375. PTC Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at 8.6. Please be aware that the consensus of earnings estimates for PTC Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.PTC Therapeutics Earnings Estimation Breakdown
The calculation of PTC Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of PTC Therapeutics is estimated to be -0.2175 with the future projection ranging from a low of -0.87 to a high of 0.2375. Please be aware that this consensus of annual earnings estimates for PTC Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.87 Lowest | Expected EPS | 0.24 Highest |
PTC Therapeutics Earnings Projection Consensus
Suppose the current estimates of PTC Therapeutics' value are higher than the current market price of the PTC Therapeutics stock. In this case, investors may conclude that PTC Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and PTC Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 15 | 61.87% | 0.0 | -0.2175 | 8.6 |
PTC Therapeutics Ownership Allocation
The majority of PTC Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to secure positions in PTC Therapeutics to benefit from reduced commissions. Therefore, outside corporations are subject to a different set of regulations than regular investors in PTC Therapeutics. Please pay attention to any change in the institutional holdings of PTC Therapeutics as this could imply that something significant has changed or is about to change at the company.PTC Therapeutics Profitability Analysis
The company reported the previous year's revenue of 806.78 M. Net Loss for the year was (363.3 M) with profit before overhead, payroll, taxes, and interest of 1.28 B.About PTC Therapeutics Valuation
The stock valuation mechanism determines PTC Therapeutics' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of PTC Therapeutics based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of PTC Therapeutics. We calculate exposure to PTC Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PTC Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 861.8 M | 904.9 M | |
| Pretax Profit Margin | (0.41) | (0.43) | |
| Operating Profit Margin | (0.34) | (0.35) | |
| Net Loss | (0.41) | (0.43) | |
| Gross Profit Margin | 0.84 | 0.88 |
PTC Therapeutics Growth Indicators
Investing in growth stocks can be very risky. If the company such as PTC Therapeutics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 76.8 M | |
| Forward Price Earnings | 55.5556 |
PTC Therapeutics Current Valuation Indicators
PTC Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final PTC Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as PTC Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use PTC Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes PTC Therapeutics' worth.Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.